-
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
The TORCHLIGHT study assessed the efficacy and safety of first-line treatment with Toripalimab plus nab-paclitaxel (n=353; experimental group) compared to placebo plus nab-paclitaxel (n=178; control group) in female patients with…
-
TED TALK | Professor Jiang Zefei: From Treatment to Cure in HER2-Positive Breast Cancer
“Women are the sky, and men are the earth. Only when women are well, can men stand tall.” Under the spotlight, Professor Jiang Zefei slowly stepped onto the center stage.…
-
SGBCC 2023 | Professor Jiang Zefei: From Early to Advanced Stage, Abemaciclib Aids HR+ Breast Cancer Patients in Achieving Comprehensive Benefits
oncology frontier : The development of CDK4/6 inhibitors has brought more possibilities for the treatment of hormone receptor-positive breast cancer. Could you please discuss the role and status of CDK4/6…
-
Dr. Wenshi Wang’s Team: Three Latest Research Findings on Hepatitis D and Hepatitis E Included in Conference Exchange
Hepatitis D (HDV) is a viral hepatitis caused by hepatitis D virus (HDV) infection, often occurring as a co-infection or superinfection with hepatitis B virus (HBV). Approximately 90% of chronic…
-
IAS 2023 | WHO Guidelines Update: The Risk of HIV Sexual Transmission with Low Viral Load is Nearly Zero
The 12th International AIDS Society Conference on HIV Science (IAS 2023) began on July 23, 2023, in Brisbane, Australia. At the conference, experts from the World Health Organization (WHO) introduced important updates to the HIV guidelines, emphasizing the importance of “HIV viral suppression for improved individual health and reduced transmission.” On the eve of the…
-
IAS 2023 | Joining Hands to Eliminate AIDS Epidemic by 2030
On July 23, 2023, the 12th International AIDS Society (IAS) HIV Science Conference, referred to as IAS 2023, officially began in Brisbane, Australia. As one of the largest open academic conferences in the global HIV and AIDS field, the event attracted participation from experts, medical professionals, community groups, and medical enterprises worldwide. The conference emphasized…
-
IAS 2023 | Thymosin α1 Therapy for HIV Immunological Non-responders: A Single-arm Clinical Study
As HIV treatment enters the post-ART era, drug side effects and complications have become significant factors affecting the quality of life for patients. Approximately 20% of patients, after 1-2 years of treatment, have viral loads below the detectable limit, but their CD4 cell count remains below normal levels, leading to poorer clinical outcomes. From 2021…
-
Dr. Weiming Tang: Exploring Crowdsourced Partner Notification Services for High-Risk HIV Populations
In China, the transmission of HIV (Human Immunodeficiency Virus) primarily occurs through sexual transmission. [1] Partner notification services help those who are HIV-positive inform their sexual partners of their infection status and guide these partners to undergo HIV testing. [2] Thus, it is crucial for identifying newly infected individuals and preventing further HIV transmission. [3]…
Connecting Medical Expertise through Media